Francesco Malorgio

Pescara, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Corrigendum to "Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed" [Eur J Cancer 202, May 2024, 114006].

Corrigendum to "Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed" [Eur J Cancer 202, May 2024, 114006].

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 27, 2026

Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study.

Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study.

Journal: Tumori

Published: May 04, 2026

Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.

Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 29, 2024

The lack of head-to-head randomised trials and the consequences for patients and national health service: The case of non-small cell lung cancer.

The lack of head-to-head randomised trials and the consequences for patients and national health service: The case of non-small cell lung cancer.

Journal: European journal of clinical pharmacology

Published: August 29, 2023

Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment.

Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment.

Journal: Oncotarget

Published: January 08, 2020

Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.

Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.

Journal: Oncoimmunology

Published: October 05, 2019

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.

Journal: Journal for immunotherapy of cancer

Published: December 04, 2018

Listening understanding and acting (lung): focus on communicational issue in thoracic oncology.

Listening understanding and acting (lung): focus on communicational issue in thoracic oncology.

Journal: Translational cancer research

Published: November 28, 2018

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.

Journal: Clinical lung cancer

Published: October 03, 2018

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.

Journal: The oncologist

Published: September 22, 2018

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: August 22, 2015

Showing 1-11 of 11

Last Updated: 09/26/2026